Drug

Permethrin

58 flagged reaction(s) · 1,086 total co-reports · max PRR 18.6

Important: Reactions below are the flagged terms from this drug’s FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate disproportionality in spontaneous reporting, not causation. Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.

	Reaction	Co-reports (a)	PRR	ROR	Signal
1	Scratch	16	18.6	18.7	signal
2	Economic Problem	23	17.9	18.2	signal
3	Anhedonia	39	17.7	18.1	signal
4	Skin Infection	14	15.1	15.2	signal
5	Skin Haemorrhage	18	15.0	15.1	signal
6	Hair Texture Abnormal	16	14.3	14.4	signal
7	Application Site Pain	26	14.2	14.4	signal
8	Incorrect Product Administration Duration	22	13.0	13.2	signal
9	Product Administered At Inappropriate Site	19	12.6	12.7	signal
10	Application Site Pruritus	21	11.1	11.2	signal
11	Osteopenia	14	11.0	11.1	signal
12	Chronic Kidney Disease	67	10.5	10.9	signal
13	End Stage Renal Disease	13	8.5	8.5	signal
14	Scab	8	8.5	8.5	signal
15	Psoriatic Arthropathy	28	8.4	8.5	signal
16	Inappropriate Schedule Of Drug Administration	49	8.2	8.4	signal
17	Decreased Activity	7	7.9	7.9	signal
18	Skin Irritation	29	7.6	7.7	signal
19	Bone Density Decreased	20	7.6	7.7	signal
20	Skin Disorder	21	7.6	7.7	signal
21	Incorrect Drug Administration Duration	18	7.6	7.6	signal
22	Nerve Injury	7	7.5	7.6	signal
23	Drug Exposure During Pregnancy	21	7.3	7.4	signal
24	Folliculitis	6	7.0	7.0	signal
25	Application Site Rash	8	7.0	7.0	signal
26	Application Site Irritation	7	6.8	6.8	signal
27	Sleep Disorder Due To A General Medical Condition	9	6.7	6.7	signal
28	Bone Disorder	10	6.5	6.6	signal
29	Dry Skin	71	6.5	6.7	signal
30	Drug Ineffective For Unapproved Indication	30	6.5	6.6	signal
31	Incorrect Route Of Product Administration	9	6.4	6.5	signal
32	Burning Sensation	37	6.3	6.5	signal
33	Body Temperature Decreased	5	6.0	6.1	signal
34	Application Site Erythema	12	5.5	5.5	signal
35	Skin Burning Sensation	31	5.2	5.3	signal
36	Eye Irritation	23	5.0	5.0	signal
37	Bone Loss	6	4.7	4.8	signal
38	Emotional Distress	48	4.7	4.9	signal
39	Expired Product Administered	13	4.7	4.7	signal
40	Metastases To Central Nervous System	5	4.7	4.7	signal
41	Alopecia	69	4.2	4.3	signal
42	Pain Of Skin	9	4.0	4.0	signal
43	Hair Colour Changes	4	3.8	3.8	signal
44	Psoriasis	38	3.5	3.5	signal
45	Drug Toxicity	4	3.5	3.5	signal
46	Tooth Loss	6	3.5	3.5	signal
47	Rebound Effect	3	3.2	3.2	no signal
48	Device Deployment Issue	3	3.0	3.0	no signal
49	Injection Site Discolouration	3	2.9	2.9	no signal
50	Multiple Fractures	4	2.9	2.9	no signal
51	Dermatitis Atopic	12	2.9	2.9	signal
52	Wrong Technique In Product Usage Process	40	2.4	2.4	signal
53	Accidental Exposure To Product	19	2.3	2.3	signal
54	Therapeutic Response Shortened	6	2.3	2.3	no signal
55	Complication Of Device Insertion	3	1.9	1.9	no signal
56	Drug Effective For Unapproved Indication	4	1.6	1.6	no signal
57	Extrapyramidal Disorder	3	1.4	1.4	no signal
58	Drug Dependence	10	0.7	0.7	no signal